| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| AXITINIB
| AXITINIB | ANTINEOPLASTIC AGENT | ORAL | Cmax 0.072 MICROMOLAR (5 MILLIGRAM TWICE DAILY) F 58 PERCENT (5 MILLIGRAM) VD 160 LITER (5 MILLIGRAM TWICE DAILY) PPB 99 PERCENT Cl 38 LITER / HOUR HT 4.3 HOUR (5 MILLIGRAM TWICE DAILY) SOLUBILITY IN AQUEOUS MEDIA OVER THE RANGE PH 1.1 TO PH 7.8 IS IN EXCESS OF 0.2 MICROGRAM / MILLILITER | RECEPTOR TYROSINE KINASES VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS VEGFR-1 VEGFR-2 VEGFR-3 PDB 4WA9 (THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB) LIGAND CODE = AXI (link to the list of PDB complexes) Download experimental 3D coordinates of AXI with added hydrogens | Vascular endothelial growth factor receptor 1 UNIPROT P17948 FLT1 -- Vascular endothelial growth factor receptor 2 UNIPROT P35968 KDR more at DrugCentral | EMA | |||
